Forma Life Sciences, which inherited BioDuro’s California production operations earlier this year, has officially ...

After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S.

Galderma has significantly raised its peak annual sales estimate for Nemluvio (nemolizumab) to more than $4 billion | Galderma has doubled its peak annual sales estimate for Nemluvio (nemolizumab) to ...

Leo Pharma has decided “It’s GO time” for the launch of its JAK inhibitor cream Anzupgo. | Leo Pharma has decided “It’s GO time” for the launch of its JAK inhibitor cream Anzupgo. Having built its ...

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...

One of the most powerful voices in the biopharma industry, Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp ...

Not long after Novo Nordisk received an untitled letter from the FDA disputing certain elements of the first TV spot for its ...

Esperion has acquired Corstasis Therapeutics and its nasal spray Enbumyst, which was approved by the FDA six months ago.

Sanofi is betting $1.53 billion on a novel drug from Sino Biopharmaceutical, securing global rights to a first-in-class JAK/ROCK inhibitor that could play a double role in the French pharma’s ...

Vanda Pharmaceuticals’ seven-year ambition to score a coveted label expansion for sleep drug Hetlioz has taken an unusual turn, with the FDA acquiescing to a formal hearing on the matter. | The ...

Acadia Pharmaceuticals isn’t taking its recent rejection from the European Medicines Agency lying down, vowing to seek a ...